Grade My Investments
HomeFree Stock Grades › AXGN

AxoGen, Inc. (AXGN) Stock Grade

AXGN · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$1.5B
P/E Ratio
Revenue Growth (YoY)
+20.2%
Net Margin
-7.0%
Return on Equity
Dividend Yield
None

About AxoGen, Inc.'s fundamentals

AxoGen is a medical device company with a market capitalization of $1.5 billion that is experiencing strong revenue growth of 20.2% year-over-year, indicating expanding sales momentum in its business. However, the company is currently unprofitable, operating at a net margin of -7.0% and reporting a net loss in its latest annual statement, which means it is spending more than it earns. The company does not pay a dividend, which is typical for growth-stage medical device companies still investing heavily to develop and commercialize their products.

Track AXGN free — no credit card required. Live grade + monthly AI report →